Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Item
http://www.wikidata.org/entity/Q27853194
CIViC databaseTranslating neoadjuvant therapy into survival benefits: one size does not fit all.New generation of breast cancer clinical trials implementing molecular profiling.Identification of Genetic and Epigenetic Variants Associated with Breast Cancer Prognosis by Integrative Bioinformatics Analysis.Lipid raft-mediated miR-3908 inhibition of migration of breast cancer cell line MCF-7 by regulating the interactions between AdipoR1 and Flotillin-1.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.Research needs in breast cancer.Targeted adjuvant therapy in breast cancer.Adjuvant trastuzumab: a 10-year overview of its benefit.Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series
P2860

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Item
http://www.wikidata.org/entity/Q27853194
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@ast
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@en
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@nl
type
label
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@ast
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@en
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@nl
prefLabel
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@ast
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@en
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015
@en
P2093
P304
P31
P356
10.1016/J.BREAST.2015.07.034
P407
P478
P50
P577
P5875
P698
P921